Nantahala Capital Management’s Cytokinetics CYTK Stock Holding History

Nantahala Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-150,000	Closed	-$8.24M	–	157
2025 Q3	$8.24M	Buy	+150,000	New	+$6.18M	0.29%	77
2024 Q1	–	Sell	-110,017	Closed	-$9.19M	–	128
2023 Q4	$9.19M	Sell	110,017 -69,240	-39%	-$2.51M	0.55%	39
2023 Q3	$5.28M	Hold	179,257	–	–	0.45%	51
2023 Q2	$5.85M	Buy	179,257 +149,257	+498%	+$5.52M	0.57%	47
2023 Q1	$1.06M	Buy	30,000 +25,198	+525%	+$1.03M	0.08%	95
2022 Q4	$220K	Buy	+4,802	New	+$207K	0.01%	109

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Nantahala Capital Management's CYTK Position: Q4 2025 in Review

Nantahala Capital Management sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 150,000 shares — an estimated $8.24M sold.

Nantahala Capital Management first reported a position in CYTK in Q4 2022 and held it in 6 quarters. The position peaked at $9.19M in Q4 2023. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

Nantahala Capital Management reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
Nantahala Capital Management sold 150,000 Cytokinetics shares in Q4 2025, an estimated $8.24M.
Nantahala Capital Management first reported a position in Cytokinetics in Q4 2022 and held it in 6 quarters.
Nantahala Capital Management's Cytokinetics position peaked at $9.19M in Q4 2023.
430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Nantahala Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.